A study to find the highest dose of ASTX727 in combination with filgrastim as a treatment option after hematopoietic stem cell transplant in children with high-risk acute myeloid leukemia

Full Title

A Phase 1 Study of Oral Cedazuridine and Decitabine Combination (ASTX727, NSC# 820631) and Filgrastim as Maintenance Therapy Post-Hematopoietic Stem Cell Transplant in Children with High-Risk Acute Myeloid Leukemia (PEPN2413) (CIRB)

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Maria Sulis’s office at 212-639-5175.

Protocol
26-237
Phase
Phase I (phase 1)
Investigator
Maria Luisa Sulis
Co-Investigators
Andrew Harris
Diseases
Leukemia › Acute Myelocytic Leukemia
Leukemia › Acute Myelogenous Leukemia
Locations
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov ID
NCT07012044
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description